The USFDA has recently issued an emergency use authorization (EUA) for the treatment of COVID-19 patients. Adults and pediatric patients with mild to moderate COVID-19 infection can now be treated with a combination of casirivimab and imdevimab.
Drug Class: Monoclonal antibodies Indication: Age ≥ 12 Weight ≥ 40 kg or 80 pounds COVID-19 positive Elderly Patients with comorbidities Before hospitalization Contraindication: Hospitalized cases Patients requiring oxygen support Patients on ventilators Route of administration: Intravenous (IV) infusion Side effects: Fever Chills Itching and flushing Hives Anaphylactic and infusion reactions This approval is based on a clinical study demonstrating the effectiveness of casirivimab and imdevimab. Study details are as follows: Study type- Randomized, double-blind, placebo-control Subjects- 799 mild-moderate, non-hospitalized, COVID-19 patients…
